Navigation Links
Mindray's AS3000(TM) Anesthesia Delivery System Receives U.S. FDA Clearance
Date:6/12/2008

SHENZHEN, China, June 12 /Xinhua-PRNewswire-FirstCall/ -- Mindray Medical International Limited (NYSE: MR) ("Mindray"), a leading developer, manufacturer and marketer of medical devices worldwide, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (the "FDA") for its AS3000 next generation anesthesia delivery system (the "AS3000") developed by Datascope Patient Monitoring, a Mindray company ("DPM").

"We're optimistic about the addition of this powerful anesthesia workstation to our growing portfolio of FDA approved medical devices and comprehensive suite of product offerings," said Mr. David Gibson, DPM's president. "The AS3000 enables us to expand our base of physiologic monitoring throughout the peri-operative environment, increase our market share in the anesthesia delivery systems market and further strengthen our leading position in ambulatory surgery centers and community hospitals."

The AS3000 delivers precision anesthesia and ventilation assistance with an intuitive design developed to bring a higher level of ergonomics to the operating room. The AS3000 is designed specifically to penetrate the anesthesia delivery systems market within the U.S., which is a market that the company estimates will generate approximately US$250 million in 2008. The system provides enhanced inhalation anesthesia and ventilation support capabilities for a variety of anesthesia cases and critical care settings, including hospitals, health clinics, outpatient and ambulatory surgery centers, specialty and surgical hospitals. The new system can be easily integrated with existing DPM monitors including the recently launched Spectrum OR and Gas Module III and will notably expand market coverage of the DPM Anesthesia product line.

"The high quality, competitively priced AS3000 is a testimony of our commitment to leverage a global R&D platform in order to tailor products by functionality and price and move up the value chain," said Mr. Xu Hang, Mindray's chairman and co-chief executive officer. "We're encouraged by this approval, the combined efforts of our world-class China-based and DPM engineering teams and the future potential of this complementary fit of assets."

Mindray noted that this FDA clearance is part of the company's strategic focus to gain market share within the peri-operative markets which has been strengthened by the acquisition of Artema Medical and the recent release of the Spectrum OR anesthesia monitor.

Mindray has to date received FDA 510(k) clearance for a total of 16 products, covering patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems; DPM has to date received FDA 510(k) clearance for a total of 9 products.

About Mindray Medical International Limited

Mindray is a leading developer, manufacturer and marketer of medical devices worldwide. Established in 1991, Mindray offers a broad range of products across three primary business segments: patient monitoring & life support products, in-vitro diagnostic products and medical imaging systems. Mindray is globally headquartered in Shenzhen, China, with U.S. headquarters in Mahwah, New Jersey. Mindray also has sales and service offices internationally in Amsterdam, Istanbul, London, Mexico City, Moscow, Mumbai, Sao Paulo, Seattle, Toronto and Vancouver. For more information, please visit http://www.mindray.com .

About Datascope Patient Monitoring

DPM develops, manufactures and markets proprietary patient monitoring products and medical devices for clinical healthcare markets in cardiology, radiology, anesthesiology, emergency medicine and critical care. The company's products are sold throughout the world through direct sales representatives and independent distributors.

Acquired by Mindray in May 2008, DPM is headquartered in Mahwah, New Jersey. For more information, please visit DPM's website at http://www.datascopemonitors.us.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about new product releases and regulatory approvals are forward- looking statements. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. Forward-looking statements involve inherent risks and uncertainties. Information regarding these risks and uncertainties is included in our public documents filed with the Securities and Exchange Commission. For a discussion of some of the risks and important factors that could affect Mindray's actual results and financial condition, see "Risk Factors" in Part I, Item 3D of Mindray's Annual Report on Form 20-F for the fiscal year ended December 31, 2006 and "Operating and Financial Review and Prospects" in Part I, Item 5 of Mindray's Annual Report on Form 20-F for the fiscal year ended December 31, 2006. All information and forward-looking statements provided in this press release are as of June 12, 2008, and Mindray undertakes no duty to update such information or forward-looking statements, except as required under applicable law.

For investor and media inquiries please contact:

In US:

Thomas Bielan

Chief Financial Officer

Datascope Patient Monitoring, a Mindray company

Tel: +1-800-288-2121

Website: http://www.datascopemonitors.us

In China:

Susan Du

Mindray Medical International Limited

Tel: +86-755-2658-2518

Email: Susan.Du@Mindray.com


'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
2. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
3. Safer, Simpler, Better & Cost Effective Cosmetic Surgery Anesthesia
4. Anesthesia Drugs Market to Grow to $4.3 Billion by 2011 as Populations and Uses for Anesthesia Increase
5. Epidemic of Anesthesia Overdosing ... How Can You Avoid It?
6. British Royal highlights anesthesia crisis in the developing world
7. Anesthesia Pouch Allows Children to Go Home Sooner After Surgery
8. Donde West Death Highlights Unnecessary Risk of General Anesthesia for Cosmetic Surgery, Asserts Dr. Friedberg
9. Donde West Likely Killed by Need to Control Postop Pain After Cosmetic Surgery, States Dr. Barry Friedberg, a Globally Recognized Leader in Cosmetic Surgery Anesthesia.
10. Awake the Movie Highlights the Need for Goldilocks Anesthesia, Says Dr. Barry L. Friedberg, Developer of Bispectral Index (BIS) Monitored Propofol Ketamine Sedation, Now Trademarked as Minimally Invasive Anesthesia (MIA)(R)
11. Experts Agree That One Case Is Too Many; Tackle Tough Issue of Anesthesia Awareness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
Breaking Medicine Technology: